Index

ABCD rule, 180–181
ABCD2 rule, 90, 180–181
abdominal aortic aneurysm, 314
abdominal pain, 309
clinical protocols, 514
diagnostic approach formulating, 263
discharge criteria, 514
disposition criteria, 301, 514
evidence basis, 449–450, 462–463
exclusion criteria, 301, 306, 309, 514
gastroparesis, 310
in geriatric observation medicine, 306
in IBD, 310
inclusion criteria, 306, 309, 514
initial diagnostic approach, 263
inpatient admission, 514
management, 310
observation, 265–266
observation unit interventions, 514
order sets
allergies in, 602–603
medications, 603–604
nursing interventions in, 602
respiratory interventions in, 603
vital signs in, 602
pediatric observation, 301–302
presentation of, 309
risk management, 46
threshold, 263–264
abdominal trauma
evidence basis, 454–455
order sets, 713–715
medications, 714–715
ABN. See Advanced Beneficiary Notice
absence seizures, 201
ACA. See affordable care act
ACC. See Alternate Care Center
Accelerated Diagnostic Treatment Center (ADTC), 512
access to care, 81–82
ACE. See angiotensin-converting enzyme
ACEP. See American College of Emergency Physicians
acetaminophen, 313, 752–754
order sets, 733, 735
toxicology
admission criteria, 323–324
contraindications to admission, 323–324
discharge criteria, 324
management, 324
ACOs. See Acute Care Organizations
ACS. See acute coronary syndrome action potential, 202, 205–206
acuity metrics, 52
acuity ranking, 38
Acute Care Organizations (ACOs), 77, 382, 478
CMS on, 92
components of, 93–94
defining, 92–93
development of, 395
health care industry and, 92
HMO compared with, 92–93
Medicare on, 93
observation medicine and, 93
observation units and, 93–94
skeptic) on, 92–93
acute care staffing, 28
acute coronary syndrome (ACS), 98, 101–102, 124, 127, 410
diagnosis, 103
disposition, 103
German observation medicine, 413
immediate management, 103
acute decompensated heart failure (ADHF), 107
acute hemolytic transfusion reaction (AHTHR), 255
acute intoxication, 515–516
acute low back pain, 314–315
Acute Medical Units (AMUs), 95
guidelines, 95
observation medicine and, 95–96
outcomes, 96
size of, 96
standards for, 95
variability in, 95
Acute Medicine, 95–96
development of, 95
patient safety in, 95
acute myocardial infarctions (AMIs), 23, 108, 413
adenosine, 127–129
adenosine triphosphate (ATP), 139–140
adenyl cyclase, 139–140
ADHF. See acute decompensated heart failure
Administrative policies
advanced practice providers (APPs) in the observation unit, 6
care coordinator, 570–571 (See also case manager)
charge nurse, 571–572
change of shift, 572
communication board, 572–573
continuing (ongoing) care of patients in the observation unit, 573–574
data base for the observation unit, 574–575
disposition of OU patients: admission to inpatient floor from OU, 576
disposition of OU patients: discharge from OU, 576–577
documentation: nursing, 577–579
documentation: physician, 579–580
medical director of observation unit, 581–582
metrics for the observation unit, 582–584
mission statement, 585
nurse manager for the observation unit, 585–586
nursing scope of patient care (nursing services provided to OU patients), 586–588
nursing responsibilities, 588–589
nursing and ancillary staffing for the observation unit, 589–590
organizational structure of the unit, 590–591
patient criteria for placement in the OU: patients meeting specific clinical criteria, 580

© in this web service Cambridge University Press
www.cambridge.org
Administrative policies (cont.)
patient criteria for placement in
the OU: patients not meeting
specific clinical criteria, 580
patients placed in the observation
unit (observation status),
574, 576–577, 583, 588, 590,
628, 745
patient selection for the
observation unit, (patients
placed in the observation
unit) 258–260
patients with infectious diseases,
580, 583
performance improvement
(continuous quality
improvement), 48, 292
physician availability, 6
physician responsibility for the
observation unit, 575
physician staffing (coverage) for
the observation unit, 5, 39
quality indicators for the
observation unit, 582
residents/fellows in the
observation unit, 578
administrative protocols, 513 (See
also Administrative policies)
admission criteria. See also exclusion
criteria; inclusion criteria; inpatient admission, clinical
protocols
acetaminophen toxicology, 323–324
benzodiazepines toxicology, 324
bupropion toxicology, 325
carbon monoxide toxicology, 326
crotalid envenomation toxicology,
328
HF, 111
Latrodectus mactans
envenomation, 328
neurotoxicity, 327
opioids toxicology, 326
pediatric observation, 302
SCD, 246–247
sulfonlurea toxicology, 325
VOC, 246–247
ADTC. See Accelerated Diagnostic
Treatment Center
adult generic order set, 748–751
Advanced Beneficiary Notice
(ABN), 364–365, 372
Advanced Practice Clinicians
(APC), 5–6, 33–34 (See also advanced practice
practitioners (APP), mid-
level providers, nurse
practitioners, physician
assistants)
EDOU, 35
responsibilities of, 6
in stakeholder analysis, 384
Advanced Practice Providers (APP),
5–6
Advanced Trauma Life Support
(ATLS), 318–319
aerosols, 606, 612, 631
Aetna, 370–371
AF. See atrial fibrillation
Affordable care act (Obamacare),
92
Agency See Healthcare Research and
Quality (AHRQ), 107
age-related observation, 478–479
future of, 484
geriatic patients, 483
discussion, 483
inclusion criteria, 301
methodology, 479
pediatric results, 479–482
costs in, 479–482
dehydration, 481
discussion, 482–483
morbidity in, 481
readmission rates, 481
reocurrence rates, 481
return visits, 481
satisfaction, 482
in United States, 484
AHA. See American Heart
Association
AHRQ. See Agency for Healthcare
Research and Quality
AHTR. See acute hemolytic
transfusion reaction
AICA. See anterior inferior
cerebellar artery
albuterol, 146–147, 740, 759
alcohol, 337
alcoholism, 46–47
allergic reaction
in abdominal pain order set,
602–603
clinical protocols, 514–515
contrast, 747, 760–761
discharge criteria, 515
disposition criteria, 515
exclusion criteria, 514
inclusion criteria, 514
inpatient admission, 515
observation unit interventions,
515
rattlesnake bites, 556
timeframe, 515
alpha2-adrenergic agonists,
657
altered mental status
clinical protocol, 515–516
disposition criteria, 516
exclusion criteria, 306, 515
geriatic observation medicine,
306
inclusion criteria, 305, 515
inpatient admission, 516
management, 305–306
observation unit interventions,
515–516
order sets, 608–610
medications for, 609–610
patient identification, 333–334
Alternate Care Center (ACC),
340–341
alternative care facilities
in disasters, 339–341
setup of, 341
staffing, 341
aluminum hydroxide, 746
Alvarado score, 404
AMA. See American Medical
Association
Ambulatory Payment Classification,
24–25, 360
American College of Cardiology, 25,
98, 107, 114–115
American College of Emergency
Medicine, 32
American College of Emergency
Physicians (ACEP), 23–24,
536
literature classification schema,
469, 503
American College of Nuclear
Cardiology, 25
American Heart Association
(AHA), 25, 98, 107, 114–115
American Medical Association
(AMA), 24
on medical necessity, 371
aminoglycosides, 281
aminophylline, 140
amiodarone, 115
AMIs. See acute myocardial
infarctions
amoxicillin, 754
with clavulanic acid, 754–755
order sets, 735
ampicillin, 151, 755
order sets, 735
with sulbac tam, 735, 755
AMUs. See Acute Medical Units
analgesics order sets, 733–735
ancillary staffing, 31–32
background, 589
EDOU, 35
objectives, 589
policies, 589
ancillary testing, 394
angioedema, 606–607
clinical protocols, 514–515
discharge criteria, 515
disposition criteria, 515
inclusion criteria, 514
inpatient admission, 515
observation unit interventions,
515
order sets, 604–605
nursing interventions, 605
respiratory interventions, 605
timeframe, 515
angiotensin receptor blocker (ARB), 82, 236–237
angiotensin-converting enzyme (ACE), 82, 236–237
inhibitors, 657
for HF, 110–111
antacids, 604, 639, 652, 746
anterior inferior cingulate artery (AICA), 220
Anthem, 370–371
antianginal agents, 623
antibiotic therapy, 721
intravenous, 612, 620, 761
oral, 612, 620, 631
order sets, 735–737
SSTIs, 261
antibiotic treatment, 146–147
acute bronchitis, 511
cellulitis, 257 (See also skin/soft tissue infections, SSTI)
chronic bronchitis, 147
COPD, 147
Pneumonia, 151
anticholinergics, 146–147
anticoagulation, 116, 615, 703–704
bridging, 160
in ED, 173
excessive, 174–175
observation care, 177
for PE, 169
for stroke, 185
vitamin K reversal, 175
antiabetic agents, 637
antiemetics order sets, 737–738
antiepileptic drugs, 206
antidiastines, 651
antiplatelet agents, 615, 623
antipyretics, 733–735
antireflux medications, 604
antithrombotic agents, 704
antitusives, 738–739
anxiety, 481
defined, 333
anxiolytics, 757
aortic dissection, 98, 314
APC. See Advanced Practice Clinicians
apical pneumothoraces, 155
exclusion criteria, 548
APP. See Advanced Practice Providers
appendicitis, 264–265
appropriate level of care, 23
ARB. See angiotensin receptor blocker
armamentarium, 140
arteriovenous malformation (AVM), 201
ASPECT study, 103
aspirin, 752
order sets, 733
for stroke prevention, 184
Assistant Secretary for Preparedness and Response (ASPR), 339–341
asthma
clinical protocols, 511–512
cost of care of, 138, 480
death rates, 138
definition, 138
discharge criteria, 517
disposition criteria, 140–141, 517
in emergency department, 138
evidence basis, 445–447
exclusion criteria, 138–140, 516
inclusion criteria, 138–140, 516
inpatient admission, 517
medications, 139–140, 759
observation unit interventions, 516–517
order sets, 611–613
medications, 612–613
in pediatric patients, 480
prevalence of, 138
risk factors, 141
risk management, 46
severity, 139
in Singapore observation medicine, 405
treatment in observation unit, 139
treatment strategies, 138
ATLS. See Advanced Trauma Life Support
atonic, 201
atorvastatin, 741–742
ATP. See adenosine triphosphate
atrial fibrillation (AF), 473
clinical protocols, 517–518
demographics and, 114
discharge criteria, 517
disposition criteria, 517–518
evidence basis, 461–462
exclusion criteria, 118–119, 517
inclusion criteria, 118–119, 517
inpatient admission, 517
management of, 115–117
observation, 119
observation unit interventions, 517
order sets
cardiac medications, 615
nursing interventions, 614
respiratory interventions, 614
vital signs, 613
paroxysmal, 114–115
pathophysiology, 114–115
prevalence of, 114
Australasian observation wards culture, 407
diagnostic group guidelines, 407
ED proximity, 406
Emergency Physician in, 406
exclusion criteria, 406–407
impact of, 407
inclusion criteria, 406–407
management plans, 407
minimum requirements, 406–407
model of care, 406
time limits, 407
aviation flight team model, 48
AVM. See arteriovenous malformation
azithromycin, 755
order sets, 736
baby boomers, 483–484
back pain
acute low, 314–315
clinical protocols, 518
discharge criteria, 518
disposition criteria, 518
exclusion criteria, 518
inclusion criteria, 518
inpatient admission, 518
observation unit interventions, 518
order sets, 616–618
medications, 617–618
barium enema, 481
bathroom facilities, 39
benchmarks, CQI, 53–54
beneficiaries, 767
beneficiary notices, 364–365
benign paroxysmal positional vertigo (BPPV), 212, 215–218
benzodiazepines
order sets, 739
toxicology
admission criteria, 324
contraindications to admission, 324
discharge criteria, 324
management, 324
reversal, 325
best practices
EDOU, 478
operations, 24
reimbursement and, 356–357
beta adrenergic agonists, 146
beta blockers, 656–657
beta-blockers, 115, 131
bicarbonate therapy, 228
biomarkers, 108
bipolar disorder, 333
bisacodyl, 746
bisphosphonate therapy, 238
Blatchford system, 267–268
bleeding, 173
major, 174–175
Index

bleeding (cont.)
minor, 174–175
risks, 174–175
Blue Cross Blue Shield, 378
BNP. See B-type natriuretic peptide
bowel ... Pain Evaluation
Registry
chest pain, 27–28, 88, 98–99, 127, 520
cardiac markers, 101–102

Center for Health Policy Research, 92
Center for Medicare and Medicaid (CMS), 13–14, 25, 76, 355, 363, 430–431, 766
on ACOs, 92
APC 8002–8003, 386
CERT development by, 373
claims data, 76
cost savings in, 391
efficiency, 394–395
finances in, 392–394
first steps, 391–392
forecasting, 392
future trends, 395
healthcare services, 391
healthcare services, 391
needs for, 391
operational oversight, 395
quality in, 392–394
stakeholder analysis, 382–384
SWOT in, 382
C1 esterase inhibitor concentrate, 606
CAD. See coronary artery disease
calcitonin gene-related peptide
(CGR), 193
calcium, 237
calcium channel blockers, 115, 131, 657
calcium oxalate, 274
call back programs, 6
CALs. See Coding Analyses for Labs
cAMP. See cyclic adenosine
monophosphate
Canadian Registry, 268
CAP. See community acquired
pneumonia
CARASI, 150
carbon monoxide toxicity
admission criteria, 326
contraindications to admission, 326
discharge criteria, 326
management, 326
cardiac imaging, 183–184
Cardiac magnetic resonance imaging
(CMR), 103
characteristics, 130
stress, 130
cardiac markers, 101–102
cardiac medications
chest pain, 623–624
congestive heart failure, 626–628
hypertension, 656–658
order sets, 740–741
cardiac studies, 60
in observation unit, 40
order sets, 732
cardiac tamponade, 98
cardio/pulmonary department,
patient recognition, 37
cardioversion, 115
care coordination, 367
carotid artery duplex ultrasound, 183
carotid endarterectomy (CEA), 185
CARSi, 150
Case Management Society of
America (CMSA), 367
Casualty transport systems (CTS), 340–341
cauda equina syndrome, 314
CDC. See Center for Disease
Control
CDR. See clinical decision rules
CDU. See Clinical Decision Unit
CEA. See carotid endarterectomy
cefazolin, 755
order sets, 736
ceftriaxone, 755
order sets, 736
cellulitis, 73–74, 257
clinical priorities, 518–519
discharge criteria, 519
disposition criteria, 519
evidence basis, 454
exclusion criteria, 518–519
inclusion criteria, 518
inpatient admission, 519
observation unit interventions, 519
order sets, 619–621
medications, 620–621
census
daily, 40–41
hourly, 40–41
observation unit, 40
center for Disease Control (CDC), 580
CHEER. See Chest Pain Evaluation
in the Emergency Room
CHEOPS. See Children’s Hospital of
Eastern Ontario Pain Scale
CHEPER. See Chest Pain Evaluation
Registry
chest pain, 27–28, 88, 98–99, 127, 520
cardiac markers, 101–102
Index

causes of, 98
CK-MB and, 102
Clinical Protocols, 511–512
costs of, 127
CQI, 104
dischage criteria, 520
disposition, 520
electrocardiogram for, 101
evidence basis, 430–431, 460
exclusion criteria, 100, 519
inclusion criteria, 100, 519
LOS and, 98–99
myoglobin and, 102
observation unit, 100–101
interventions, 519
observation usage rate, 89
order sets, 622–624
cardiac medications, 623–624
OU, 31
pathophysiology, 99
provocative stress test and, 103
review of admissions, 374
risk management, 46
risk scores, 100
risk stratification, 99–100
troponin and, 102
units, 127
Ches Pain Evaluation in the Emergency Room (CHEER), 99
Ches Pain Evaluation Registry (CHEPER), 98
cheat pain units (CPUs)
concept of, 413–415
establishment of, 413
in German observation medicine, 413, 415
chest radiographs (CSR), 153
CHF. See congestive heart failure
children’s hospital
emergency medicine in, 302
pediatric observation, 300–302
research in, 302
Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS), 312
chlamydia, 284
Christmas disease, 254
chronic bronchitis, 143–144
antibiotic treatment, 147
chronic obstructive pulmonary disease (COPD), 143
antibiotic treatment, 147
clinical presentation, 144–145
definition, 144
differential diagnosis, 145
dischage criteria, 521
disposition, 147, 521
ED management, 145
evidence basis, 456
exclusion criteria, 520–521
inclusion criteria, 520
inpatient admission, 521
mortality, 143
observation unit interventions, 521
observation unit management, 145–147
order set, 630–632
medications, 630–632
pathophysiology, 143–144
predictors of poor outcome in, 145
risk factors, 144
shortness of breath in, 144–145
in Singapore observation medicine, 405
stage I, 144
stage II, 144
stage III, 144
timeframe, 521
chronic pain
of malignancy, 315
management, 315
Cigna, 378
CIGNA, 370–371
ciprofloxacin, 281
order sets, 736
CK-MB, 102
clavulanic acid, 735
amoxicillin with, 754–755
cloxacillin, 151, 755–756
order sets, 736
clinical care pathways
initiation of, 58
nurse staffing, 31–32
Clinical Data Abstraction Center, 20
clinical decision rules (CDR), 165–166
Clinical Decision Unit (CDU), 51, 95–96, 268, 812
EMU shift from, 422
meetings, 53–54
rattlesnake bites in, 563
staff requirements, 58–59, 68
Clinical Protocols, 511–512
abdominal pain, 514
acute intoxication, 515–516
allergic reaction, 514–515
altered level of consciousness, 515–516, 608–609 (See also altered mental status)
altered mental status, 515–516
angioedema, 514–515
asthma, 511–512, 516–517
atrial fibrillation, 517–518
back pain, 518
cellulitis, 518–519 (See also skin infections, soft tissue infections, SSTI)
chest pain, 511–512, 519–520
chronic obstructive pulmonary disease (COPD), 511
complex, 512
deep vein thrombosis (DVT), 158–159, 165, 539 (See also venous thromboembolic disease)
dehydration, 521–522
dengue, 512
diagnoses in, 511
diarrhea, 521–522
dizziness, 79 (See also vertigo)
electrolyte abnormalities, 523–524
exclusion criteria, 511
extremity infections, 524–525
flank pain (See also renal colic)
fluctuations in, 512
gastrointestinal bleeding, 525–526
generic, 526–527
headaches, 527–528
headaches with a shunt (See also headaches)
heart failure, 528–529
hematuria, 529
HG, 529–530
hyperalgesia, 523–524
hyperemesis gravidarum
hyperglycemia, 530–531
hyperkalemia, 523–524
hypernatremia, 523–524
hypertension, 531
hypoglycemia, 529
kidney stones (See also urolithiasis)
low risk pulmonary emboli, 567
near syncope, 289
overdose, 482
pelvic inflammatory disease, 285
pharyngitis/peritonsillar abscess, 532
pneumonia/acute bronchitis, 675–679
pylephlebitis/urinary tract infection (UTI), 404
renal colic, 263 (See also flank pain)
seizures, 535
skin infections (See also cellulitis, skin and soft tissue infections, soft tissue infections, SSTI)
sickle cell disease, 535
snakebites, 556–559, 560–564
soft tissue infections, 257–262, 516
spontaneous pneumothorax, 153–157, 546–555
SSTI (skin and soft tissue infections) (See also cellulitis, skin infections, soft tissue infections)
Syncope/Near Syncope, 536–537, 690–691
Clinical Protocols (cont.)
Transfusion, 537
transient ischemic attack, 537
trauma – abdominal, 539–540
trauma – isolated chest injury, 716–718
trauma – extremity injury, 722
trauma – head injury, 543
vaginal bleeding, 287–288
vertigo, 522–523 (See also dizziness)
venous thromboembolic disease, 702–704 (See also deep vein thrombosis [DVT], pulmonary emboli [PE])
inclusion criteria, 511
rattlesnake bites, 556–558
specialized, 548
spectrum of disease in, 511–512
substance abuse, 515–516
uncomplicated, 512
vertigo, 522–523
vomiting, 521–522
clinical technicians, 589
clodipogrel, 184
closed unit, 3
clustering, 38
CMR. See cardiac magnetic resonance imaging
CSMA. See Case Management Society of America
CNS. See central nervous system
codeine, 313
pharmacokinetic properties, 313
promethazine and, 738–739
Code of Federal Regulations (CFR), 370
coding, 348
medical necessity, 386–387
Coding Analyses for Labs (CALs), 372
cohorting, 38
advantages of, 37
Colombian emergency services, 425
color coding, 37
observation unit patient, 37–38
Commission on Professional and Hospital Activities, 370
Comorbidity, 79, 305, 483
Complications, 73, 165, 175, 222
communication
pediatric patients, 291
in risk management, 44
communication boards for patient rooms
background, 572
objectives, 572
policy, 572–573
community acquired pneumonia
(CAP)
definitions, 149
disposition, 151
in ED, 149–150
exclusion criteria, 150–151
hospitalization factors, 150–151
inclusion criteria, 150–151
initial management, 149–150
likely organisms in, 151
mortality rate, 149
prevalence of, 149
risk factors, 149–150
TIA, 183
treatment, 151
community hospital perspective
observation medicine, 58–59
pediatric observation in, 59
comorbidities, 20, 73
Compare Worksheet, 15
complex observation, 12–15
compliance oversight, 361
Comprehensive Error Rate Testing (CERT), 19–20
CMS and, 373
development of, 373
improper payment determinations in, 374
compression ultrasound (CUS), 159–160, 167
computed tomography (CT), 413–415, 750, 764
kidney stones, 276
order sets, 672
de syncoupe, 124
treated tomography angiogram
(CTA), 103, 166
TIA, 183
treated tomography coronary angiography
(CTCA), 130
characteristics, 131
Condition Code 44, 364
Condition of Participation, 366
congestive heart failure (CHF), 76, 99, 116, 144–145
evidence basis, 451–454
order sets, 625–629
cardiac medications, 626–628
cardiac studies, 626
Census Panel, 268
Consumer Price Index, 477
continuing care policies
background, 573
objectives, 573–574
Continuous Quality Improvement (CQI), 520
benchmarks, 53–54
chest pain and, 104
components, 48
costs, 48
goals, 48
observation unit database, 49–50
observation unit documentation, 50–51
observation unit indicators, 53
observation unit metrics in, 51
OU, 48
pediatric observation, 292
contrast allergy, 747, 760–761
copays, 21
COPD. See chronic obstructive pulmonary disease
coronary artery disease (CAD), 108
pretest probability, 127–128
coronary artery stenosis, 128–130
correct status, 363–365
correlated spreading depression, 191
corticosteroids, 146, 612, 631
cortisol, 231
crash cart, 40
CQI.
CPU. See chest pain units
CQI. See Continuous Quality Improvement
CRC. See chest pain units
CQI. See Continuous Quality Improvement
CURB, 150
CroFab, 557
infusing, 556–557
mixing, 556
Crotalid envenomation toxicology
admission criteria, 328
antivenom, 329
contraindications to admission, 328
management, 328
croup, 480–481
in pediatric patients, 481–482
CRP. See C-reactive protein
Crystoscintigraphy, 253
CSF. See cerebrospinal fluid
CSM. See chest radiographs
CT. See computed tomography
CTA. See computed tomography angiogram
CTCA. See computed tomography coronary angiography
CTS. See casualty transport systems
culture reports, 6
Curb, 150
private payer observation codes, 357
CUS. See compression ultrasound
CVA. See cerebrovascular accident
Cyclic adenosine monophosphate (cAMP), 139–140, 204–206
CYP1A2, 173–174
CYP2C9, 173–174
CYP3A4, 173–174
cystitis, 281
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>dabigatran, 116–117</td>
</tr>
<tr>
<td>dalteparin, 743</td>
</tr>
<tr>
<td>database background, 574</td>
</tr>
<tr>
<td>demographic, 575</td>
</tr>
<tr>
<td>key elements, 574</td>
</tr>
<tr>
<td>objectives, 574</td>
</tr>
<tr>
<td>policy, 574</td>
</tr>
<tr>
<td>reimbursement, 575</td>
</tr>
<tr>
<td>DCCT. See Diabetes Control and Complications Trial</td>
</tr>
<tr>
<td>D-dimer, 166</td>
</tr>
<tr>
<td>deep vein thrombosis (DVT), 159</td>
</tr>
<tr>
<td>discharge criteria, 162</td>
</tr>
<tr>
<td>in EDOU, 161–162</td>
</tr>
<tr>
<td>evidence basis, 460</td>
</tr>
<tr>
<td>exclusion criteria, 162</td>
</tr>
<tr>
<td>inclusion criteria, 162</td>
</tr>
<tr>
<td>management, 161–162</td>
</tr>
<tr>
<td>medications, 703–704</td>
</tr>
<tr>
<td>order sets, 742–743</td>
</tr>
<tr>
<td>outcome, 163</td>
</tr>
<tr>
<td>treatment, 160</td>
</tr>
<tr>
<td>Defendant Physician, 46</td>
</tr>
<tr>
<td>dehydration, 289</td>
</tr>
<tr>
<td>clinical protocols, 521–522</td>
</tr>
<tr>
<td>discharge criteria, 522</td>
</tr>
<tr>
<td>evaluation, 271–272</td>
</tr>
<tr>
<td>exclusion criteria, 272, 521</td>
</tr>
<tr>
<td>inclusion criteria, 272, 521</td>
</tr>
<tr>
<td>inpatient admission, 522</td>
</tr>
<tr>
<td>intervention, 272</td>
</tr>
<tr>
<td>management, 272</td>
</tr>
<tr>
<td>observation unit interventions, 521–522</td>
</tr>
<tr>
<td>order sets, 633–635</td>
</tr>
<tr>
<td>medications, 634–635</td>
</tr>
<tr>
<td>pathophysiology, 271</td>
</tr>
<tr>
<td>delayed hemolytic transfusion reactions (DHTRs), 255</td>
</tr>
<tr>
<td>delirium, 333–334</td>
</tr>
<tr>
<td>dementia, 334</td>
</tr>
<tr>
<td>Demming approach, 48</td>
</tr>
<tr>
<td>demographic variables, 583</td>
</tr>
<tr>
<td>AF and, 114</td>
</tr>
<tr>
<td>database, 575</td>
</tr>
<tr>
<td>inpatient admission, 565</td>
</tr>
<tr>
<td>Department of Health and Human Services (DHHS), 366</td>
</tr>
<tr>
<td>depolarization, 203–204</td>
</tr>
<tr>
<td>designation, 333</td>
</tr>
<tr>
<td>desmopressin, 253–254</td>
</tr>
<tr>
<td>chest pain, 520</td>
</tr>
<tr>
<td>dehydration, 522</td>
</tr>
<tr>
<td>DVT, 162</td>
</tr>
<tr>
<td>extremity infections, 525</td>
</tr>
<tr>
<td>generic protocols, 527</td>
</tr>
<tr>
<td>headaches, 528</td>
</tr>
<tr>
<td>HG, 111</td>
</tr>
<tr>
<td>HG, 530</td>
</tr>
<tr>
<td>observation unit, 516</td>
</tr>
<tr>
<td>PE, 162</td>
</tr>
<tr>
<td>PSP, 155</td>
</tr>
<tr>
<td>rattlesnake bites, 558</td>
</tr>
<tr>
<td>trauma, 321</td>
</tr>
<tr>
<td>vertigo, 522–523</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press
www.cambridge.org
disproportionate share hospital (DSH), 18–19
disseminated intravascular coagulation (DIC), 251–253
biuretics, 626, 628
HF for, 110
order sets, 741
Dix-Hallpike maneuver, 215–216
dizziness, 211
causes of, 220
classification, 211–212
differential, 211–212
history, 211–212
physical examination, 212–215
DKA. See diabetic ketoacidosis
dobutamine, 103, 127–129
douqi, 746
DOJ. See Department of Justice
dorsal raphe nucleus, 193
dorsal root ganglion, 195
double dipping, 387
DRG. See diagnosis related group
Drug Information Handbook, 513
DSH. See disproportionate share hospital
DTI. See direct thrombin inhibitors
Duke Treadmill Score (DTS), 128
DVT. See deep vein thrombosis
DWI. See diffusion weight imaging
dyspnea, 108
EC. See electrical cardioversion
ECG. See electrocardiogram
echocardiography
stress, 130
characteristics, 131
for syncope, 124
economical service, 29
ECoW. See emergency center observation wards
ED. See emergency department
EDOU. See Emergency Department Observation Unit
EDTU. See Extended Diagnostic Treatment Unit
education
indirect medical, 18–19
introduction of, 66
observation medicine, 66–67
patient, 111
PGY-1, 66
PGY-2, 66
required qualifications, 66–67
EF. See ejection fraction
Effectiveness and Safety of Chest Pain Assessment to Prevent Emergency Admission (ESCAPE), 99
EHR. See electronic health record
ecography
injection fraction (EF), 111
elderly population, 77. See also geriatric patients
pam management in, 314
electrical cardioversion (EC), 115
urographplainogram (ECG)
for chest pain, 101
for STEMI, 101
stress, 128
urographplainographic monitoring, 124
electrolyte abnormalities, 235
calcium, 237
clinical protocols, 523–524
discharge, 523
disposition, 523–524
exclusion criteria, 523
inclusion criteria, 523
inpatient admission, 523
magnesium, 239
observation unit interventions, 523
order sets, 705–706
potassium, 235
sodium, 240
timeframe, 523
electrolyte replacements
hypocalcemia, 706–707
hypokalemia, 708
hypomagnesemia, 710
hypophosphatemia, 712
electrocardiogram (EKG), 523
electrocardiographic monitoring, 124
Electronic health record (EHR), 395
electronic medical records (EMR), 426
checklists, 376
electronic records, 31
observation unit database, 50
electrophysiology
AF, 114–115
of syncope, 124
EM. See emergency medicine
Emergency Advisors, 424
Emergency Center, 400
emergency center observation wards
(EOWC)
emergency contraindications, 401–402
admission to, 399–401
criteria, 401
diagnostic evaluation, 401
management procedures, 400–401
psychosocial needs in, 401
short term therapy, 401
in South Africa, 398–399
Emergency Centers, 398
emergency department (ED), 300, 766
anticipated volume, 31
anticoagulation, 173
asthma in, 138
Australasian observation ward proximity to, 406
CAP in, 149–150
complaints in, 127
COPD management, 145
efficiency, 457–458
evaluation, 38–39
expansion projects, 31
metrics, 52
number of patients in, 583
OU differentiated from, 64
patient evaluation, 43
patient volumes, 72
paediatric, 46
increases in visits, 482
returns to, 295–296
pneumonia in, 149
psychiatric patients in, 332
rattlesnake bite evaluation, 563
restrictions, 45
seizures, 200
in TIA, 182
toxicologic disorder visits, 323
transfer times from, 31
urban community hospital, 60
waiting rooms, 43
Emergency Department Observation Unit (EDOU), 33
admissions, 74
ancillary staffing, 35
APCs, 35
beds, 74
on best practices, 478
consultants, 35
culture, 74
DVT in, 161–162
efficiency in, 72
evidence-based protocols, 72–73
exclusion criteria, 73
facilities, 74
geriatric patients in, 483
inclusion criteria, 73
intervention, 73–74
leadership, 33
literature, 72
management, 73–74
needs, 74
nurses, 33
physicians, 33
population in, 72–73
space for, 33
Emergency Medical Treatment and Labor Act (EMTALA), 342
Emergency Medical Unit (EMU), 421
CDU shifted to, 422
emergency medicine (EM)
in children’s hospitals, 302
components of, 72
observation medicine and, 68
in South Africa, 398
Emergency Medicine Residents Association, 68
Emergency Medicine Society of South Africa (EMSSA), 398
Emergency Operations Center (EOC), 339
Emergency Physician, 380
in Australasian OW, 406
in medical necessity denials, 380
rights for, 406
emphysema, 143
EMR. See electronic medical records
EMSSA. See Emergency Medicine Society of South Africa
EMTALA. See Emergency Medical Treatment and Labor Act
EMU. See Emergency Medical Unit
English Common Law, 45
enoxaparin, 160–161, 743
Enteropectin, 280
entry criteria, 109–110
EOC. See Emergency Operations Center
epilepsy, 200
definition, 201
pathophysiology, 205–206
patient evaluation, 207–208
patient selection, 208
epinephrine, 231
Epley maneuver, 216
erythrocyte sedimentation rate (ESR), 197
erythromycin, 286
ESC. See European Society of Cardiology
ESCAPE. See Effectiveness and Safety of Chest Pain Assessment to Prevent Emergency Admission
ESR. See erythrocyte sedimentation rate
eszopiclone, 739
ethanol, 332
European Society of Cardiology (ESC), 101–102, 114–115, 167
evening shift, 40–41
evidence basis, 430–431
abdominal pain, 449–450, 462–463
abdominal trauma, 454–455
AF, 461–462
asthma, 445–447
cellulitis, 454
chest pain, 430–431, 460
clinical findings, 505–506
congestive heart failure, 451–454
COPD, 456
criteria for, 471
critical questions, 468, 472
downgrading strength, 468–470, 504–505
DVT, 460
ED efficiency, 457–458
future research, 468
geriatric patients, 486–501
head injury, 450–451, 463
level A recommendations, 472
level B recommendations, 472, 472–473
level C recommendations, 472
methodology, 431
pediatric patients, 486–501
pneumonia, 456
results, 431–467
SCD, 462
summary, 466–468
syncope, 447–449
TIA, 460
toxicoology, 455–456, 463
excitatory neurotransmitters, 204–205
exclusion criteria. See also admission criteria; inclusion criteria
abdominal pathophysiology, 301, 306, 309, 514
af, 118–119, 517
age-related observation, 477–506
allergic reaction, 514
altered mental status, 306, 515
angioedema, 514
apical pneumothoraces, 548–549
asthma, 138–140, 516
Australasian observation wards, 406–407
back pain, 518
CAP, 150–151
cellulitis, 518–519
central nervous system shunt, 222
chest pain, 100, 519
clinical protocols, 511
COPD, 520–521
dehydration, 272, 521
dengue fever, 565
DVT, 162
EDOU, 73
electrolyte abnormalities, 523
extended observation, 73
extremity infections, 524
falls, 305
gastrointestinal bleeding, 525
generic protocols, 526
geriatric observation medicine, 305
headaches, 527
heart failure, 528
hematuria, 529
HF, 110
HG, 529–530
hyperkalemia, 530
hypertension, 531
PSP, 155, 546
rheumatoid arthritis, 551
seizures, 208
syncope, 123
trauma, 319
upper gastrointestinal bleeding, 267
vertigo, 522
exercise
provocative stress test, 103
readmissions and, 81
Extended Diagnostic Treatment Unit (EDTU), 565
extended observation, 12–15
comprehensive teams, 77
cost effectiveness, 76
exclusion criteria, 73
financial concerns, 77
inclusion criteria, 73
LOS, 73
management, 73–74
pathophysiology, 73
patient discharge, 76
staff, 77
trend towards, 76
unit flow, 76–77
External Review, 379
extremity infections
clinical protocols, 524–525
discharge criteria, 525
disposition criteria, 525
exclusion criteria, 524
inclusion criteria, 524
inpatient admission, 525
observation unit interventions, 524–525
timeframe, 525
extremity trauma order sets, 720–722
facility reimbursement, 24–25, 360–361
Medicare rates, 360–361
factor deficiencies, 253
factor IX deficiency, 254
factor V Leiden deficiency, 251
factor deficiencies, 253
facility reimbursement, 24–25
Medicare rates, 360–361
factor deficiencies, 253
factor IX deficiency, 254
factor V Leiden deficiency, 251–252
factor VIII deficiency, 253
factor deficiencies, 253–254
factor Xa inhibitors, 703
factor XI deficiency, 251–252
factor XIII, 253
falls, 305
exclusion criteria, 305
in geriatric observation medicine, 304
inclusion criteria, 304
mechanical, 320
famotidine, 746, 760
fast-track patients, 41
fibrinolysis, 200
febrile reactions (FNHTR), 255
fibrinolysis, 200
febrile seizures, 200
fellowships, 68
fentanyl, 313, 752–753
order sets, 733–734
pharmacokinetic properties, 313
FFP. See fresh frozen plasma
FI. See Fiscal Intermediaries
fibrinogen deficiency, 253
financial viability, 24–25
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>finger stick glucose determination, 371</td>
</tr>
<tr>
<td>First Level review, 378–379</td>
</tr>
<tr>
<td>Fiscal Intermediaries (FI), 15, 373–374</td>
</tr>
<tr>
<td>claims appeals, 378</td>
</tr>
<tr>
<td>FISS (See Fiscal Intermediary Standard Systems) flexible staffing, 4</td>
</tr>
<tr>
<td>Fiscal Intermediary Standard Systems fluoroquinolones, 151, 281</td>
</tr>
<tr>
<td>FNHTF. See febrile non-hemolytic transfusion reactions</td>
</tr>
<tr>
<td>follow-up phone calls, 82</td>
</tr>
<tr>
<td>fondaparinux, 169, 743</td>
</tr>
<tr>
<td>Fourth Level appeal, 379</td>
</tr>
<tr>
<td>Framingham Study, 115</td>
</tr>
<tr>
<td>French observation medicine, 411</td>
</tr>
<tr>
<td>organization, 411</td>
</tr>
<tr>
<td>palliative care in, 411</td>
</tr>
<tr>
<td>perspectives on, 411</td>
</tr>
<tr>
<td>social workers in, 411</td>
</tr>
<tr>
<td>fresh frozen plasma (FFP), 251–253</td>
</tr>
<tr>
<td>effectiveness, 252–253</td>
</tr>
<tr>
<td>warfarin and, 252</td>
</tr>
<tr>
<td>functional physical plant, 24</td>
</tr>
<tr>
<td>Fundacion Cardio Infantil ED, 424</td>
</tr>
<tr>
<td>care at, 424</td>
</tr>
<tr>
<td>challenges in, 425</td>
</tr>
<tr>
<td>Pneumatic Tube Transport System, 426</td>
</tr>
<tr>
<td>special units, 426</td>
</tr>
<tr>
<td>furosemide, 110, 741, 759</td>
</tr>
<tr>
<td>protocol, 627</td>
</tr>
<tr>
<td>GABA. See gamma-aminobutyric acid</td>
</tr>
<tr>
<td>gamma-aminobutyric acid (GABA), 196, 205</td>
</tr>
<tr>
<td>gastroenteritis, 481</td>
</tr>
<tr>
<td>gastroenterologists, 512</td>
</tr>
<tr>
<td>gastrointestinal bleeding</td>
</tr>
<tr>
<td>clinical protocols, 523–526</td>
</tr>
<tr>
<td>discharge criteria, 526</td>
</tr>
<tr>
<td>disposition criteria, 526</td>
</tr>
<tr>
<td>exclusion criteria, 525</td>
</tr>
<tr>
<td>inclusion criteria, 525</td>
</tr>
<tr>
<td>inpatient admission, 526</td>
</tr>
<tr>
<td>observation unit interventions, 525</td>
</tr>
<tr>
<td>order sets, 638–640</td>
</tr>
<tr>
<td>medications, 640–652</td>
</tr>
<tr>
<td>timeframe, 526</td>
</tr>
<tr>
<td>gastrointestinal studies, 732</td>
</tr>
<tr>
<td>gastroparesis, 310</td>
</tr>
<tr>
<td>GCS. See Glasgow Coma Scale</td>
</tr>
<tr>
<td>GDO. See Goal Directed Outcomes</td>
</tr>
<tr>
<td>gender, readmissions and, 81</td>
</tr>
<tr>
<td>general trauma medications for, 724–725</td>
</tr>
<tr>
<td>order sets, 725</td>
</tr>
<tr>
<td>generalized seizures, 201</td>
</tr>
<tr>
<td>Geneva risk score, 168</td>
</tr>
<tr>
<td>geriatric patients, 304, 501–502</td>
</tr>
<tr>
<td>acute abdominal pain in, 306</td>
</tr>
<tr>
<td>age-related observation, 483</td>
</tr>
<tr>
<td>discussion, 483</td>
</tr>
<tr>
<td>altered mental status, 305</td>
</tr>
<tr>
<td>comorbidities in, 483</td>
</tr>
<tr>
<td>costs of, 483–484</td>
</tr>
<tr>
<td>in EDOU, 483</td>
</tr>
<tr>
<td>evidence basis, 486–501</td>
</tr>
<tr>
<td>exclusion criteria, 305</td>
</tr>
<tr>
<td>falls in, 304</td>
</tr>
<tr>
<td>fractures in, 304</td>
</tr>
<tr>
<td>inclusions, 304</td>
</tr>
<tr>
<td>LOS for, 483</td>
</tr>
<tr>
<td>management, 304–305</td>
</tr>
<tr>
<td>mobility in, 304–305</td>
</tr>
<tr>
<td>orthostatic instability, 304–305</td>
</tr>
<tr>
<td>outcome, 304–305</td>
</tr>
<tr>
<td>in United States, 483–484</td>
</tr>
<tr>
<td>geriatric services, 60</td>
</tr>
<tr>
<td>German observation medicine</td>
</tr>
<tr>
<td>ACS in, 413</td>
</tr>
<tr>
<td>background, 413</td>
</tr>
<tr>
<td>chest pain units in, 413, 415</td>
</tr>
<tr>
<td>clinical need, 413</td>
</tr>
<tr>
<td>Glasgow Coma Scale (GCS), 319, 320</td>
</tr>
<tr>
<td>Global Initiative for Chronic Obstructive Lung Disease (GOLD), 144</td>
</tr>
<tr>
<td>glucagon, 231, 233</td>
</tr>
<tr>
<td>glycemic thresholds, 232</td>
</tr>
<tr>
<td>Goal Directed Outcomes (GDO), 421–422</td>
</tr>
<tr>
<td>Goal Directed Therapy, 421–422</td>
</tr>
<tr>
<td>GOLD. See Global Initiative for Chronic Obstructive Lung Disease</td>
</tr>
<tr>
<td>graded exercise testing, 124</td>
</tr>
<tr>
<td>Graff, Louis, 403</td>
</tr>
<tr>
<td>group homes, 343–344</td>
</tr>
<tr>
<td>growth hormone, 231</td>
</tr>
<tr>
<td>guaifenesin, 738</td>
</tr>
<tr>
<td>dextromethorphan and, 738</td>
</tr>
<tr>
<td>Haemophilus influenzae, 147</td>
</tr>
<tr>
<td>HAP. See hospital acquired pneumonia</td>
</tr>
<tr>
<td>HBV. See hepatitis B virus</td>
</tr>
<tr>
<td>HCA. See health care assistant</td>
</tr>
<tr>
<td>HCAP. See healthcare associated pneumonia</td>
</tr>
<tr>
<td>HCC cardiac risk score tool, 90</td>
</tr>
<tr>
<td>HCP. See healthcare professionals</td>
</tr>
<tr>
<td>HCP-CS. See Healthcare Common Procedure Coding System</td>
</tr>
<tr>
<td>HCV. See hepatitis C virus</td>
</tr>
<tr>
<td>head injury analgesics for, 727–728</td>
</tr>
<tr>
<td>antiemetics for, 728</td>
</tr>
<tr>
<td>evidence basis, 450–451, 463</td>
</tr>
<tr>
<td>intravenous fluids for, 728</td>
</tr>
<tr>
<td>order set, 728</td>
</tr>
<tr>
<td>medications, 727–728</td>
</tr>
<tr>
<td>pathophysiology, 320</td>
</tr>
<tr>
<td>head pain, 46</td>
</tr>
<tr>
<td>headaches</td>
</tr>
<tr>
<td>anatomy, 191–194</td>
</tr>
<tr>
<td>biochemical basis, 193–194</td>
</tr>
<tr>
<td>cellular basis of, 193–194</td>
</tr>
<tr>
<td>classifications, 190</td>
</tr>
<tr>
<td>clinical protocols, 527–528</td>
</tr>
<tr>
<td>definition, 189</td>
</tr>
<tr>
<td>discharge criteria, 528</td>
</tr>
<tr>
<td>disposition criteria, 527–528</td>
</tr>
<tr>
<td>exclusion criteria, 527</td>
</tr>
<tr>
<td>inclusion criteria, 527</td>
</tr>
<tr>
<td>inpatient admission, 527–528</td>
</tr>
<tr>
<td>medications for, 743–745</td>
</tr>
<tr>
<td>in observation unit, 197</td>
</tr>
<tr>
<td>observation unit interventions, 527</td>
</tr>
<tr>
<td>order sets, 641–642</td>
</tr>
<tr>
<td>medications, 642–643</td>
</tr>
<tr>
<td>pathophysiology of, 190–191</td>
</tr>
<tr>
<td>patient selection, 196–197</td>
</tr>
<tr>
<td>pharmacologic management, 197–198</td>
</tr>
<tr>
<td>prevalence of, 189</td>
</tr>
<tr>
<td>primary, 189–190</td>
</tr>
<tr>
<td>secondary, 189–190</td>
</tr>
<tr>
<td>sensitization, 194</td>
</tr>
<tr>
<td>with shunt, 646–647</td>
</tr>
<tr>
<td>specific therapy, 197</td>
</tr>
<tr>
<td>spinal, 643, 745</td>
</tr>
<tr>
<td>timeframe, 528</td>
</tr>
<tr>
<td>Health and Human Services (HHS), 372–373</td>
</tr>
<tr>
<td>health care</td>
</tr>
<tr>
<td>ACO and, 92</td>
</tr>
<tr>
<td>costs, 45</td>
</tr>
<tr>
<td>readmissions, 81–82</td>
</tr>
<tr>
<td>in United States, 45</td>
</tr>
<tr>
<td>spending, 484</td>
</tr>
<tr>
<td>utilization, 81–82</td>
</tr>
<tr>
<td>health care assistant (HCA), 422</td>
</tr>
<tr>
<td>Health Information and Portability Act (HIPPA), 49</td>
</tr>
<tr>
<td>Health Information Management (HIM), 359</td>
</tr>
<tr>
<td>Health Net, 370–371</td>
</tr>
<tr>
<td>Health Resources Service Administration (HRSA), 339–341</td>
</tr>
<tr>
<td>health care associated pneumonia (HCAP), 149</td>
</tr>
<tr>
<td>Healthcare Common Procedure Coding System (HCPCS), 50378, 375</td>
</tr>
<tr>
<td>Healthcare Financial Management Association, 355</td>
</tr>
<tr>
<td>Healthcare Insurance Claim Number, 22</td>
</tr>
</tbody>
</table>
Index

hypoglycemia (cont.)
risk factors, 231
hypokalemia, 235–236
management, 236
oral replacement, 708
order sets, 707–708
electrolyte replacements, 708
symptoms, 235–236
treatment, 235
hypomagnesemia, 239
electrolyte replacements, 710
intraavenous fluids, 710
oral replacement, 710
order sets, 709–710
treatment, 239–240
hyponatremia, 81, 240
treatment, 241
hypophosphatemia, 241
electrolyte replacement, 712
intraavenous fluids, 712
oral replacement, 712
order sets, 710–712
treatment, 241
hypoxia, 146–147

IBD. See inflammatory bowel disease
ibuprofen, 313, 753
order sets, 734
ICD. See International Classification of Diseases
ICD-9-CM, 19, 372 See International Classification of Diseases 9th revision
ICD-10-CM, 19, 359 See International Classification of Diseases 10th revision
ICU. See intensive care unit
idiopathic thrombocytopenic purpura (ITP), 255
IDSA. See Infectious Diseases Society of America
IME. See indirect medical education
Imitrex, 643, 646
inclusion criteria. See also admission criteria; exclusion criteria
abdominal pain, 309, 514
AF, 118–119, 517
age-related observation, 477–506
allergic reaction, 514
altered mental status, 305, 515
angioedema, 514
apical pneumothoraces, 548
asthma, 138–140, 516
Australian observation wards, 406–407
back pain, 518
cellularis, 518
central nervous system shunt, 222
chest pain, 100–109
clinical protocols, 511
COPD, 520
dehydration, 272, 521
dengue fever, 565
DVT, 162
EDOU, 73
electrolyte abnormalities, 523
extended observation, 73
extremity infections, 524
falls, 304
gastrointestinal bleeding, 525
generic protocols, 526
geriatric observation medicine, 304
headaches, 527
heart failure, 528
hematuria, 529
hyperglycemia, 531
hypertension, 531
medical necessity screening tools, 17
Medicare Part A, 21
observation and, 17–18
observation usage rate and, 27–28
threshold for, 27–28
vertigo, 522
inpatient beds, 38
Inpatient Prospective Payment System (IPPS), 16
defining, 18–19
DRG in, 18–19
observation and, 19
reimbursement, 19–20
inpatient status, 363
inpatient stays, 766–767
inpatient supplies, 40
inpatient units, 39
INR, 28 international normalized ratio
insulin therapy, 636
diabetes order set, 636
hyperglycemia, 227–228
sliding scale coverage, 636–637
insurance companies, 43
Integrated Output Code Editor (I/OCE), 379
International Classification of Diseases (ICD), 19
International Classification of Diseases (ICD) 9th revision (ICD-9-CM), 19
International Classification of Diseases (ICD) 10th revision (ICD-10-CM), 19
international normalized ratio (INR), 161, 167–169, 175, 252–253
interneurons, 205
InterQual, 17, 76–77, 89
CMS licensing of, 370
history of, 370
for pain management, 315
Severity of Illness criteria, 315–316
intrapreneurship, 93
intraavenous fluids
antibiotics, 612, 620, 761
for head injury, 728
hypocalcemia, 706
hypomagnesemia, 710
medical necessity (cont.)
payment, 386–387
physician considerations in, 388
medical necessity screening tools, 17
medical records, 357
Medicare, 11
on ACOs, 93
coverage loopholes, 767
coverage problems, 767
criteria, 357
denied claims, 378
DOJ on, 374
facility reimbursement rates, 360–361
Fifth Level appeal, 379
finances of, 77
Fourth Level appeal, 379
general rules, 355–356
HP and, 107
history of, 370
maximal reimbursement, 395
observation coverage, 375
Outpatient Code Editor, 387
payment accuracy, 19–20
payment error rates, 20
physician documentation, 348, 353
modifiers, 353–354
protection of, 19–20
readmissions and, 78
reforms, 21
sample reimbursements, 353–354
Second Level review, 379
for SNF, 767
in stakeholder analysis, 383–384
Third Level appeal, 379
Medicare administrative contractors (MACs), 15
claims appeals, 378
role of, 365
work plans, 373–374
Medicare Coverage Database (MCD), 372
Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), 372
Medicare Inpatient Prospective Payment System (MIPPS), 395
Medicare Integrity Contractor, 22
Medicare Part A
coverage under, 19
deductible, 21
inpatient admission, 21
Medicare Part B
coverage under, 19
outpatient claim, 376
Medicare Payment Advisory Commission (MedPAC), 11
Medicare Quality Improvement Organization, 374
MedPAC. See Medicare Payment Advisory Commission
Medicare Severity Adjusted – DRG, 14
MEMS. See Modular Emergency Medical System
Meniere’s disease, 214–215
metabotropic receptors, 204–206
metoclopramide, 737
metoprolol, 741
metrics
background, 582
clinical, 583
discussion, 583–584
objectives, 582–583
pediatric observation, 584
policy, 583
MI. See myocardial infarction
MIC. See Medicare Integrity Contractor
mildlevel provider staffing, 39
background, 584
coverage, 5–6, 33–34
discussion, 585
objectives, 584
policy, 584
staffing ratios, 39
migraine, 189, 646
anatomy, 191–194
pathophysiology of, 191
theories on, 191
Milliman care guidelines, 17, 76–77
MIPPS. See Medicare Inpatient Prospective Payment System
missed diagnosis rate, 27
threshold for observation, 88
mission statement
background, 585
discussion, 585
objectives, 585
policy, 585
mobility, 304–305
mOBRI. See Modified Outpatient Bleeding Risk Index
Modified Outpatient Bleeding Risk Index (mOBRI), 174
Modified Pre-Verbal, Early Verbal Pediatric Pain Scale (M-PEPPS), 312
Modular Emergency Medical System (MEMS), 340–341
Monaxella catarrhalis, 147
morning blood draws, 4
morphine, 277, 313, 753–754
order sets, 734–735
pharmacokinetic properties, 313
motor vehicle collisions (MVC), 319
M-PEPPS. See Modified Pre-Verbal, Early Verbal Pediatric Pain Scale
MPI. See myocardial perfusion imaging
MRA. See magnetic resonance angiography
MRI. See magnetic resonance imaging
MRSA infections. See methicillin resistant Staphylococcal infections
MS. See multiple sclerosis
MS-DRS. See Medicare Severity Adjusted – DRG
multi-disciplinary treatment team, 367
multiple sclerosis (MS), 214–215
MVC. See motor vehicle collisions
myocardial infarction (MI), 78, 88, 127, 520
observation units and, 98–99
myocardial perfusion imaging (MPI), 103, 128–130
stress, 131
myoglobin, 102
NA. See needle aspiration
naloxone, 327
National Center for Health Statistics (NCHS), 19
National Correct Coding Initiative (NCCI), 372
National Coverage Analyses (NCAs), 372
National Coverage Determinations (NCDs), 371–372
definition, 371
National Disaster Medical System (NDMS), 343
National Government Services, 373–374
National Health Service (NHS), 95
in Italian observation medicine, 418
National Hospital Ambulatory Medical Care Survey (NHAMCS), 382
National Incident Management System (NIMS), 341
National Institute of Health (NIH), 190
National Quality Forum (NQF), 78, 367
key measures, 368–369
National Strategy for Quality Improvement in Health Care
goals of, 366
priorities, 366
National Uniform Billing Committee (NUBC), 376
NCAs. See National Coverage Analyses
NCCI. See National Correct Coding Initiative
NCDs. See National Coverage Determinants
NCHS. See National Center for Health Statistics
NDMS. See National Disaster Medical System
needle aspiration (NA), 154
NEHC. See Neighborhood Emergency Help Center
Neighborhood Emergency Help Center (NEHC), 340–341
neurokinin A, 193
neuroleptics toxicology
admission criteria, 327
contraindications to admission, 327
charge
discharge criteria, 328
management, 327
nerve receptors, 732
neuron, 202–203
neuronal excitability, 206–207
neuronal networks, 205
neuropeptides, 193
neurotransmitters, 193
excitatory, 204–205
inhibitory, 205
anaesthetics
nurses, 589
manager
additional qualifications, 586
background, 585
discussion, 586
job description, 585–586
licensure, 586
of observation unit, 42
reporting structure, 586
roll of, 42
training, 586
mindset, 37
models, 33–34
nursing documentation
background, 577–578
discussion, 578
objectives, 578
reimbursement, 579
training, 578
nursing interventions
in abdominal pain order set, 602
in AF order sets, 614
angioedema order sets, 605
nursing responsibilities
background, 588
discussion, 589
position, 577
documentation, 589
objectives, 588
patient care, 588–589
patient satisfaction, 5
ratios, 4–5, 33–34, 38
scope of care
background, 586–587
diagnostics, 587
discussion, 587–588
monitoring, 587
objectives, 587
policy, 587
procedures, 587
standard, 587
staffing
clinical care pathways, 31–32
ratios, 4–5, 38
in stakeholder analysis, 384
training, 31–32
NYHA. See New York Heart Association
nystagmus, 213–215
obesity, 81
observation. See also pediatric observation
abdominal pain, 265–266
AF, 119
anticoagulation, 177
complex, 12–15
as correct level of care, 27–28
defining, 2
diagnostic testing in, 512
ending, 375
evidence basis, 430–431
abdominal pain, 449–450, 462–463
abdominal trauma, 454–455
AF, 461–462
asthma, 445–447
cellulitis, 454
chest pain, 430–431, 460
congestive heart failure, 451–454
COPD, 456
criteria for, 471
critical questions, 468, 472
DVT, 460
ED efficiency, 457–458
future research, 468
head injury, 450–451, 463
methodology, 431
pneumonia, 456
results, 431–467
SCD, 462
summary, 466–468
syncope, 447–449
TIA, 460
toxicology, 455–456, 463
extended, 12–15
comprehensive teams, 77
cost effectiveness, 76
exclusion criteria, 73
financial concerns, 77
inclusion criteria, 73
observation (cont.)
LOS, 73
management, 73–74
pathophysiology, 73
patient discharge, 76
staff, 77
trends towards, 76
unit flow, 76–77
increased usage of, 382
inpatient admission criteria and, 17–18
IPSS, 19
Medicare
coverage, 375
sample reimbursements, 353–354
mislabeling, 12–13
in pain management, 315–316
as payment category, 363–364
PE, 169–170
as process, 4
SCD protocol, 247
simple, 12–15
stroke, 185
threshold, 27
TIA, 181–182
trends in, 382
VOC protocol, 247
observation medicine. See also specific countries
ACOs and, 93
AMUs and, 95–96
billing, 20–21
community hospital perspective, 58–59
culture, 407
curriculum, 66
education, 66–67
introduction of, 66
PGY-1, 66
PGY-2, 66
required rotations, 66–67
EM and, 68
expanding roles of, 72
fellowships in, 68
hospitalist and, 64
importance of, 48
lectures on, 68
medical necessity and, 374–376
observation status and, 766–767
origins of, 62
readmissions and, 83
training, 66–67
in urban community hospital, 60
observation unit
ACOs and, 93–94
administration of, 42
advantages of, 590–591
alternative terms for, 512
ancillary testing, 394
asthma treatment in, 139
bathroom facilities, 39
benchmarks, 8
benefits of, 512
business plan, 8–10
cardiac patients in, 40
census, 40
chest pain, 31, 100–101
clinical benefits of, 8
closed, 3
common diagnosis in, 293
COPD management, 145–147
cost savings from, 479
CQI components, 48
cross coverage in, 5
data sets, 49
database
clinical information, 50
custom, 50
data elements, 49–50
electronic records, 50
procedures in, 49
specialized, 50
time in, 49
deaths in, 483
design, 7, 30–32, 39, 292
designated, 2–3, 64
discharge criteria, 516, 522
documentation
CQI, 50–51
procedures, 50
treatments, 50
economical service, 29
ED differentiated from, 64
efficiencies in, 394–395
emergency setting, 108–109
equipment, 7, 39, 292
financial benefits of, 8
deheads in, 197
health care crisis and, 478–479
hybrid, 3–4, 294
hyperglycemia, 226–228
hypoglycemia, 233
indicators
benchmarks, 53–54
CQI, 53
outcome, 53
process, 53
rate-based, 53
sentinel event, 53
structural, 53
intensive managerial review, 28–29
interventions
abdominal pain, 514
AF, 517
allergic reaction, 515
altered mental status, 515–516
angioedema, 515
anesthesia, 516–517
back pain, 518
cellulitis, 519
chest pain, 519
COPD, 521
dehydration, 521–522
electrolyte abnormalities, 523
extremity infections, 524–525
gastrointestinal bleeding, 525
headaches, 527
heart failure, 528
hematuria, 529
HF, 530
hyperglycemia, 530
hypertension, 531
vertigo, 522
justifications for, 391
length of stay, 4
location, 4, 31
meetings, 53–54
metrics, 8, 51
acuity, 52
complaints, 52
ED metrics and, 52
long length of stay, 51
short length of stay, 51–52
MI and, 98–99
nurse manager of, 42
open, 3
pain management protocols, 316
patient
amenities, 39
care, 39, 588–589
color coding, 37–38
grouping, 38
log, 54
placement, 37–38
recognition, 37
safety, 8
patients
amenities, 39
care, 39, 588–589
color coding, 37–38
grouping, 38
log, 54
noncompliance, 81
placement, 37–38
recognition, 37
safety, 8
selection criteria, 258–260
in stakeholder analysis, 382–384
pediatric, 7–8
performance improvement, 8
personnel, 30–31
costs of, 378
efficiency and, 31
physician coverage, 38–39, 76
physician medical director of, 41–42
pitfalls, 41
process, 30
protocol-driven, 2–3
proximity, 30
quality experience, 8

© in this web service Cambridge University Press
www.cambridge.org
reimbursement, 389
resource utilization, 72
room size, 31
rotation curriculum, 66
seizures, 208–209
size of, 7–8
estimation, 31
SSTIs, 259–260
supplies, 7, 39, 292
tailoring, 512
technology in, 39
telephone in, 39
television in, 39
TIA in, 182
time lag in, 40
toileting in, 39
toxiology, 323
types of, 2–3, 30
Observation Unit Meeting, 40
observation usage rate, 28
chest pain, 89
inpatient admission and, 27–28
threshold for admission, 89
observational status, 366, 368
changes in, 17–18
defining, 766
information sheets, 21
observation medicine and, 766–767
OCE. See Outpatient Code Editor
octreotide, 233
OESL. See Osservatorio Epidemiologicosulla
Sincopenel Lazio
Office of Inspector General (OIG), 21, 361, 382, 766
annual work plan, 372–373
improper payment determinations in, 374
ofloxacin, 286
OIG. See Office of Inspector General
omepazole, 745, 759–760
ondansetron, 290, 756–757
order sets, 737
one-day inpatient hospital stays, 20
OP measures. See outpatient measures
open unit, 3
opioids, 198, 245, 646, 745, 761
in pain control, 246, 313
for SCD, 246
toxiology admission criteria, 326
contraindications to admission, 327
discharge criteria, 327
management, 327
for VOC, 246
OPPS. See Outpatient Prospective Payment
oral antibiotics, 612, 620, 631
oral replacement, 712
order sets, 513
abdominal pain allergies in, 602–603
medications, 603–604
nursing interventions in, 602
respiratory interventions in, 603
vital signs in, 602
abdominal trauma, 713–715
medications, 714–715
acetaminophen, 733, 735
acute bronchitis, 511
adult generic, 748–751
advantages of, 513, 761
AF
cardiac medications, 615
nursing interventions, 614
respiratory interventions, 614
vital signs, 613
altered level of consciousness, 608–610 (See also altered mental status)
altered mental status, 608–610
medications for, 609–610
amoxicillin, 735
ampicillin, 735
angioedema, 733–735
aspirin, 733
asthma, 611–613
medications, 612–613
azithromycin, 736
back pain, 616–618
medications, 617–618
benzodiazepines, 739
cardiac medications, 740–741
cardiac studies, 732
cefazolin, 736
ceftriaxone, 736
cellulitis, 619–621
medications, 620–621
cephalexin, 736
chest pain, 622–624
cardiac medications, 623–624
chest trauma, 615–702
chronic obstructive pulmonary disease, 630–632
ciprofloxacin, 736
clindamycin, 736
congestive heart failure, 625–629
cardiac medications, 626–628
cardiac studies, 626
COPD, 630–632
medications, 630–632
CT, 672
dehydration, 633–635
medications, 634–635
design of, 513
diabetes, 636–637
antidiabetic agents, 637
insulin, 636
dosages in, 513
drug listings in, 513
DVT, 742–743
electrolyte abnormalities, 705–706
extremity trauma, 720–722
fentanyl, 733–734
gastrointestinal bleeding, 638–640
medications, 640–652
gastrointestinal studies, 732
general trauma, 725
head injury, 728
medications, 727–728
headaches, 641–642
medications, 642–643
with shunts, 646–647
heart failure, 625–629
hematuria, 647–649
medications, 648–649
HG, 650–652
medications, 651–652
hydrocortone, 734
hydromorphone, 734
hydroxyzine, 737
hyperglycemia, 650–658
hypertension, 655–658
hypoglycemia, 659
hypokalemia, 707–708
electrolyte replacements, 708
hypomagnesemia, 709–711
hypophosphatemia, 710–712
ibuprofen, 734
intravenous fluids, 708, 710, 729
isolated chest injury, 702
medications, 615–702
kidney stones, 660–662
laboratory tests, 730–732
levofoxacin, 736
lorazepam, 739
metoclopramide, 737
modification of, 513
morphine, 734–735
MRI, 695
neurologic studies, 732
nonbenzodiazepine hypnotics, 739–740
ondansetron, 737
overdose, 610
oxycodeone, 735
pediatic generic, 762–765
pediatic medications, 752–760
pelvic inflammatory disease (PID), 284
Index

order sets (cont.)
penicillin G, 737
penicillin V, 737
peritonsillar abscess, 532
pharyngitis, 671–674
piperacillin, 317–318
chronic pain in elderly population, 314
pain management. See also abdominal pain; chest pain
acute low back pain, 314–315
assessment, 312
chronic, 315
chronic pain of malignancy, 315
criteria for observation, 315–316
in elderly population, 314
epidemiology, 312
InterQual in, 315
medications, 316
principles, 312
in in special populations, 314
pain pathophysiology
CNS in, 196
dorsal root ganglion in, 195
periphery, 195
spinal cord in, 195
pain scale, 312
in specialists, 313–314
palliative care, 411
panic disorder, 333
pantoprazole, 746, 760
paroxysmal AF, 114–115
partial seizures, 201
pathophysiology
AF, 114–115
anti-epileptic drugs, 206
epilepsy, 205–206
extended observation, 73
head injury, 320
of headaches, 190–191
hypoglycemia, 231–232
mechanical falls, 320
of migraine, 191
MVC, 319
pain
CNS in, 196
dorsal root ganglion in, 195
periphery, 195
spinal cord in, 195
pediatric patients, 291–292
penetrating trauma, 320
rib fractures, 319–320
of seizures, 201–206
trauma, 319

Patient Placement Department, 76–77
Patient Protection Affordable Care Act, 78, 92
patients. See also geriatric patients; pediatric patients
amenities, 39
care assistants, 39
nursing responsibilities, 588–589
color coding, 37–38
grouping, 38
log, 54
noncompliance, 81
placement, 37–38
recognition, 37
cardiopulmonary department, 37
laboratory department, 37
radiology department, 37
safety, 8
selection criteria, 258–260
in stakeholder analysis, 382–384
spreadsheets, 292
in stakeholder analysis, 384
Payment Error Prevention Program, 22
PC. See pharmacological cardioversion
PCI. See percutaneous coronary intervention
PE. See pulmonary embolism
pediatric ED, 40
increases in visits, 482
returns to, 295–296
pediatric generic order set, 762–765
pediatric observation
abdominal pain, 301–302
admission criteria, 302
children's hospital, 300–302
clinical criteria, 302
in community hospital, 59
cost effective, 295
CQI, 292
design, 292–293
differences in, 292–293
ED and readmissions, 295–296
equipment, 292–293
functions of, 300–301
future of, 297
hospital admissions, 295
hybrid unit, 296
international perspective, 295
LOS, 294, 296
medications, 292–293
metrics, 584
parental satisfaction, 296
patient care quality, 295
patient satisfaction, 296
performance improvement, 292
physician satisfaction, 296
principles of, 292
supplies, 292–293
types of, 300–301
pediatric patients, 291
adult patients compared to, 294
age-related observation results, 479–482
costs in, 479–482
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>dehydration, 481</td>
</tr>
<tr>
<td>discussion, 482–483</td>
</tr>
<tr>
<td>morbidity in, 481</td>
</tr>
<tr>
<td>readmission rates, 481</td>
</tr>
<tr>
<td>reoccurrence rates, 481</td>
</tr>
<tr>
<td>return visits, 481</td>
</tr>
<tr>
<td>satisfaction, 482</td>
</tr>
<tr>
<td>asthima in, 480</td>
</tr>
<tr>
<td>background, 292</td>
</tr>
<tr>
<td>bariurn enema, 481</td>
</tr>
<tr>
<td>communication, 291</td>
</tr>
<tr>
<td>croup in, 481–482</td>
</tr>
<tr>
<td>developmental factors, 291–292</td>
</tr>
<tr>
<td>evaluation of, 291</td>
</tr>
<tr>
<td>evidence basis, 486–501</td>
</tr>
<tr>
<td>gastroenteritis, 481</td>
</tr>
<tr>
<td>intrususception, 481</td>
</tr>
<tr>
<td>LOS for, 482</td>
</tr>
<tr>
<td>medications order set, 752–760</td>
</tr>
<tr>
<td>pathophysiology, 291–292</td>
</tr>
<tr>
<td>psychosocial admissions, 482</td>
</tr>
<tr>
<td>Peer Review Organizations, 373</td>
</tr>
<tr>
<td>pelvic inflammatory disease (PID), 284</td>
</tr>
<tr>
<td>clinical diagnostic criteria, 284</td>
</tr>
<tr>
<td>diagnosis, 284–285</td>
</tr>
<tr>
<td>management, 286</td>
</tr>
<tr>
<td>oral treatment regimens, 285</td>
</tr>
<tr>
<td>parenteral treatment regimens, 285</td>
</tr>
<tr>
<td>prevalence of, 284</td>
</tr>
<tr>
<td>penetrating trauma, 320</td>
</tr>
<tr>
<td>penicillin G, 756</td>
</tr>
<tr>
<td>order sets, 737</td>
</tr>
<tr>
<td>penicillin V, 756</td>
</tr>
<tr>
<td>order sets, 737</td>
</tr>
<tr>
<td>PEPP (See Payment Error Prevention Program)</td>
</tr>
<tr>
<td>PEPPER report, 9, 373, 388–389</td>
</tr>
<tr>
<td>access, 15–16</td>
</tr>
<tr>
<td>Compare Worksheet, 15</td>
</tr>
<tr>
<td>contents of, 14–15</td>
</tr>
<tr>
<td>defining, 14</td>
</tr>
<tr>
<td>on one-day inpatient hospital stays, 20</td>
</tr>
<tr>
<td>payment errors, 16</td>
</tr>
<tr>
<td>targeted areas in, 20</td>
</tr>
<tr>
<td>two-nidnight rule and revision of, 16</td>
</tr>
<tr>
<td>uses of, 15</td>
</tr>
<tr>
<td>peptic ulcer disease (PUD), 252</td>
</tr>
<tr>
<td>percutaneous coronary intervention (PCI), 79–81</td>
</tr>
<tr>
<td>Performance Improvement (PI), 89</td>
</tr>
<tr>
<td>components, 48</td>
</tr>
<tr>
<td>costs, 48</td>
</tr>
<tr>
<td>goals, 48</td>
</tr>
<tr>
<td>pediatric observation, 292</td>
</tr>
<tr>
<td>toolbox, 48</td>
</tr>
<tr>
<td>periaguedal grey (PAG), 193</td>
</tr>
<tr>
<td>Persantine, 127–129</td>
</tr>
<tr>
<td>PESI. See Pulmonary Embolism Severity Index</td>
</tr>
<tr>
<td>pharmacologic stress agents, 127–129</td>
</tr>
<tr>
<td>pharmacological cardioversion (PC), 115</td>
</tr>
<tr>
<td>PHI See Protected Health Information</td>
</tr>
<tr>
<td>phlebotomy, 31, 37–38</td>
</tr>
<tr>
<td>phosphate, 241</td>
</tr>
<tr>
<td>physical examination</td>
</tr>
<tr>
<td>HF and, 108</td>
</tr>
<tr>
<td>physician documentation, 351</td>
</tr>
<tr>
<td>psychiatric patients, 335–336</td>
</tr>
<tr>
<td>in seizures, 207</td>
</tr>
<tr>
<td>physician coding</td>
</tr>
<tr>
<td>99217-discharge, 350</td>
</tr>
<tr>
<td>99218-initial observation, 350</td>
</tr>
<tr>
<td>99219-initial observation, 350</td>
</tr>
<tr>
<td>99220-initial observation, 350</td>
</tr>
<tr>
<td>99224-subsequent observation, 350</td>
</tr>
<tr>
<td>99226-subsequent observation, 350–351</td>
</tr>
<tr>
<td>99226-subsequent observation, 349–351</td>
</tr>
<tr>
<td>99234-observation, 349</td>
</tr>
<tr>
<td>99235-observation, 349</td>
</tr>
<tr>
<td>99236-observation, 349</td>
</tr>
<tr>
<td>99237-observation, 349</td>
</tr>
<tr>
<td>99246-observation, 349</td>
</tr>
<tr>
<td>99247-observation, 349</td>
</tr>
<tr>
<td>reimbursement in, 359</td>
</tr>
<tr>
<td>scenarios, 349–351</td>
</tr>
<tr>
<td>summary of, 349–351</td>
</tr>
<tr>
<td>coverage, 38–39</td>
</tr>
<tr>
<td>documentation, 348</td>
</tr>
<tr>
<td>background, 579</td>
</tr>
<tr>
<td>comprehensive history, 351</td>
</tr>
<tr>
<td>critical care, 354</td>
</tr>
<tr>
<td>detailed history, 351</td>
</tr>
<tr>
<td>disposition, 579–580</td>
</tr>
<tr>
<td>justifying medical necessity in, 348</td>
</tr>
<tr>
<td>Medicare, 348, 353–354</td>
</tr>
<tr>
<td>objectives, 579</td>
</tr>
<tr>
<td>ongoing evaluation, 579</td>
</tr>
<tr>
<td>physical exam, 351</td>
</tr>
<tr>
<td>prolonged services, 352</td>
</tr>
<tr>
<td>reimbursement and, 356–357</td>
</tr>
<tr>
<td>requirements, 348–349, 351</td>
</tr>
<tr>
<td>summary of, 351</td>
</tr>
<tr>
<td>EDOU, 33</td>
</tr>
<tr>
<td>medical director, 41–42</td>
</tr>
<tr>
<td>in medical necessity, 388</td>
</tr>
<tr>
<td>mindset, 37</td>
</tr>
<tr>
<td>reimbursement, 24–25</td>
</tr>
<tr>
<td>responsibilities</td>
</tr>
<tr>
<td>background, 575</td>
</tr>
<tr>
<td>disposition, 575, 577</td>
</tr>
<tr>
<td>objectives, 575</td>
</tr>
<tr>
<td>ongoing management, 575</td>
</tr>
<tr>
<td>policy, 575</td>
</tr>
<tr>
<td>staffing, 5</td>
</tr>
<tr>
<td>ratios, 39</td>
</tr>
<tr>
<td>in stakeholder analysis, 384</td>
</tr>
<tr>
<td>supervising, 35</td>
</tr>
<tr>
<td>PI. See Performance Improvement</td>
</tr>
<tr>
<td>PICA. See posterior inferior cerebellar artery</td>
</tr>
<tr>
<td>PID. See pelvic inflammatory disease</td>
</tr>
<tr>
<td>piperacillin, 756</td>
</tr>
<tr>
<td>order sets, 737</td>
</tr>
<tr>
<td>plain X-rays, 750, 764</td>
</tr>
<tr>
<td>order sets, 671</td>
</tr>
<tr>
<td>Platelet Glycoprotein IIb/IIa in Unstable Angina Using Integrelin Therapy (PURSUIT), 100</td>
</tr>
<tr>
<td>platelets, 254–255</td>
</tr>
<tr>
<td>prophylactic transfusion, 254</td>
</tr>
<tr>
<td>thresholds, 254</td>
</tr>
<tr>
<td>Pneumatic Tube Transport System, 426</td>
</tr>
<tr>
<td>pneumonia, 40, 82</td>
</tr>
<tr>
<td>in emergency department, 149</td>
</tr>
<tr>
<td>evidence basis, 456</td>
</tr>
<tr>
<td>risk factors, 149–150</td>
</tr>
<tr>
<td>pneumonia patient outcomes research time (PORT), 150</td>
</tr>
<tr>
<td>POA. See Present on Admission (POA), 372</td>
</tr>
<tr>
<td>POPE. See polyethylene glycol, 746–747, 760</td>
</tr>
<tr>
<td>polymenorrhea, 287</td>
</tr>
<tr>
<td>PORT. See pneumonia patient outcomes research time posterior inferior cerebellar artery (PICA), 220</td>
</tr>
<tr>
<td>post-transfusion purpura (PTP), 255</td>
</tr>
<tr>
<td>potassium, 624</td>
</tr>
<tr>
<td>abnormalities, 235</td>
</tr>
<tr>
<td>nomogram, 627–628</td>
</tr>
<tr>
<td>supplements, 623</td>
</tr>
<tr>
<td>PPI. See proton pump inhibitors</td>
</tr>
<tr>
<td>prednisolone, 742, 758</td>
</tr>
<tr>
<td>prednisone, 742, 758</td>
</tr>
<tr>
<td>Present on Admission (POA), 372</td>
</tr>
<tr>
<td>accuracy of, 373</td>
</tr>
<tr>
<td>Press-Ganey scores, 6</td>
</tr>
<tr>
<td>pretest probability of CAD, 127–128</td>
</tr>
<tr>
<td>stress tests and, 127–128</td>
</tr>
<tr>
<td>PRIDE study, 108</td>
</tr>
<tr>
<td>primary headache, 189–190</td>
</tr>
<tr>
<td>primary seizures, 201</td>
</tr>
<tr>
<td>primary spontaneous pneumothorax (PSP), 153–155</td>
</tr>
<tr>
<td>discharge criteria, 155–156</td>
</tr>
<tr>
<td>exclusion criteria, 155, 546</td>
</tr>
<tr>
<td>inclusion criteria, 155, 546</td>
</tr>
<tr>
<td>intervention, 155–156</td>
</tr>
<tr>
<td>large, 154</td>
</tr>
<tr>
<td>management, 155–156, 548</td>
</tr>
<tr>
<td>presentation of, 153</td>
</tr>
<tr>
<td>small, 153–154</td>
</tr>
</tbody>
</table>
Index

process indicators, 53
prochlorperazine, 757
order sets, 737–738
Program for Evaluating Payment Patterns Electronic Reports 14
prolonged services
physician documentation, 352
time thresholds, 352
promethazine, 290, 757
codeine and, 738–739
order sets, 738
Protected Health Information 22
Proteus, 280
Policies – Administrative (See Administrative Policies)
Protocols – Clinical (See clinical protocols) prothrombin time (PT), 161
protocol driven unit, 2–3
proton pump inhibitors (PPI), 268, 652, 745–746, 759–760
provider liable, 364
provoke test
chest pain and, 103
exercise, 103
proximity of observation unit, 30
Prudential, 370–371
Pseudomonas aeruginosa, 147, 280
PSI, 150
PSP. See primary spontaneous pneumothorax
psychiatric patients, 332
in ED, 332
emergencies, 332–333
imaging in, 337
medical clearance, 337
medical illnesses simulating, 334
physical examination, 335–336
present illness history in, 335
routine testing, 336–337
psychosocial admissions, 482
PT, 161, 567. See prothrombin time
PTP. See post-transfusion purpura
PUD. See peptic ulcer disease
pulmonary arterial bed, 165
pulmonary embolism (PE), 98, 159, 165, 567
anticoagulation for, 169
diagnosis, 165–167
discharge criteria, 162
inclusion criteria, 162
LOS, 165
low-risk, 167–169
mortality, 165
observation care, 169–170
outcome, 163
patient selection, 169
risk stratification, 167–169
Pulmonary Embolism Severity Index (PESI), 168
pulmonary studies, 732
PURSUIT. See Platelet Glycoprotein IIb/IIIa in Unstable Angina Using Integrilin Therapy
pyelonephritis, 281
QA. See quality assurance
QCS. See Quick Confusion Scale
QI. See quality improvement
QIC. See Qualified Independent Contractor
QIO. See Quality Improvement Organization
Qualified Independent Contractor (QIC), 379
quality assurance (QA), 73
quality improvement (QI), 73
metrics, 583
Quality Improvement Organization (QIO), 15, 373
CMS contracts with, 20
quality of care, 365
Quick Confusion Scale (QCS), 335
RAC. See recovery audit contractor
radiographic findings, 108
radiology department, 37
radiology studies
contrast allergy and, 747,
760–761
order studies, 671–695
randomized clinical trials (RCTs), 24, 154
Rapid Diagnostic and Treatment Unit (RDTU), 512
Rapid Intense Observation Unit (RIO), 72
admission rates, 72–73
management, 72–73
rate-based indicators, 53
rattlesnake bites
allergic reaction, 556
CDU protocol, 563
clinical protocols, 556–558
consults, 557–558
contraindications, 560–562
diet, 556
discharge criteria, 558
disposition, 558
ED evaluation, 563
follow-up, 558
indications, 560
labs, 557
medications, 556–557
physician orders, 558–559
severity grading, 560
RBC. See red blood cell
RBRSV. See Resource Based Relative Value Scale
RCTs. See randomized clinical trials
RDTU. See Rapid Diagnostic and Treatment Unit
readmissions
access to care and, 81–82
associated factors, 80
avoidable, 83
CMS rates, 78
costs of, 78
decreasing rates, 78, 83
demographic variables, 81
exercise and, 81
gender and, 81
health care utilization and, 81–82
hospital factors, 82
ICU, 79–81
individual factors, 81
injury and, 79
international perspective, 79
LOS, 78–79
Medicare and, 78
obesity and, 81
observation medicine and, 83
patient disease and, 79
patient noncompliance and, 81
in pediatric age-related observation, 481
pediatric observation and, 295–296
potential solutions, 82–83
problems with measuring, 79
reduction of, 79
report to Congress, 79
risk standardized, 78
seven day, 20
smoking and, 81
socioeconomic factors, 81
30-day, 78
unavoidable, 78
VHA rates, 78
receptor, 204
recovery audit contractor (RAC), 12, 14, 361, 374, 382
claims reviews of, 374
role of, 365
in tertiary care hospitals, 63
red blood cell (RBC), 275
transfusion, 250–251
recommendations, 250–251
Red Book of Pediatrics, 513
re-expansion pulmonary edema (RPE), 155
regadenoson, 127–129
regulatory billing, 31–32
reimbursement
best practice and, 356–357
composite, 360–361
database, 575
documentation requirements, 356–357
facility, 24–25, 360–361
Medicare rates, 360–361
IPSS, 19–20

© in this web service Cambridge University Press
maximal, 395
nursing documentation, 579
observation unit, 389
physician documentation and,
356–357
in revenue cycle management,
356
billing, 359–360
charging, 357–359
physician coding, 359
registration, 356
sample, 353–354
Relative Value Unit (RVU), 352–353
combined, 353
comparison of, 353
for subsequent observation, 353
Relative Value Update Committee
(RUC), 352
RE-LY trial, 116–117
renal colic, 275
renal failure, 520
reperfusion therapy, 98
Resource Based Relative Value Scale
(RBRVS), 352–353
formula, 352–353
Resource Utilization Group 22
respiratory interventions
in abdominal pain order set, 603
AF order sets, 614
angioedema order sets, 605
revenue cycle management, 355
reimbursement in, 356
billing, 359–360
charging, 357–359
physician coding, 359
registration, 356
revised Geneva score, 165–166
rib fractures
order set, 702
medications, 615–702
pathophysiology, 319–320
right ventricular dysfunction
(RVD), 167
rim pneumothoraces, 155
exclusion criteria, 551
inclusion criteria, 551
interventions, 551
RIO. See Rapid Intense Observation
Unit
risk management
abdominal pain, 46
alcoholism, 46–47
approach, 46
asthma, 46
chest pain, 46
chest pain scores, 100
communication in, 44
cost-effectiveness, 45
data, 44
decreasing risk, 46
definition, 43
diabetes, 46
function of, 43–44
goals, 46
head pain, 46
high risk situations, 45–47
ketoacidosis, 46
legal issues, 45
new modes of, 43–44
quality assurance, 44
system redesign, 46
risk stratification, 90–91
ABCD2 TIA, 90
chest pain, 99–100
PE, 167–169
TIA, 180–181
UGIB, 268
Risk Stratification of Syncope in
Emergency Department (ROSE), 121
risk-standardized readmission rates
(RSRRs), 78
rivaroxaban, 160–161
Rockall system, 267–268
ROMICAT, 103
ROSE. See Risk Stratification of
Syncope in Emergency Department
rosuvastatin, 742
RPE. See re-expansion pulmonary
edema
RSRRs. See risk-standardized
readmission rates
RUC. See Relative Value Update
Committee
RUG See Resource Utilization
Group
RVD. See right ventricular
dysfunction
RVRVS. See Resource Based Relative
Value Scale
RVU. See Relative Value Unit
SAEM. See Society for Academic
Emergency Medicine
SAH. See subarachnoid hemorrhage
San Francisco Syncope Rule (SFSR),
121
Sant’Andrea Hospital, 419
scatter beds, 4, 12
SCD. See sickle cell disease
schizophrenia, 332–333
Second Level review, 378–379
denial letter, 379
Medicare, 379
secondary headache, 189–190
secondary seizures, 201
secretaries, 39
seizures
absence, 201
classifications, 201
definitions, 200–201
in ED, 200
exclusion criteria, 208
febrile, 200
generalized, 201
inclusion criteria, 209
observation unit management,
208–209
partial, 201
pathophysiology of, 201–206
patient evaluation, 207–208
patient selection, 208
physical examination in, 207
prevalence of, 200
primary, 201
secondary, 201
threshold, 209
Seldinger technique, 154
aftercare, 555
kit content, 553–555
procedure, 553–555
self-reporting, 337
senior care crisis, 483–484
sensitization
central, 194–195
headaches, 194
sentinel event indicators, 53
seven day readmissions, 20
severity of illness (SI), 17, 19, 363
SHCN. See Special Health Care
Needs
short acting beta agonists, 146–147
short length of stay metrics, 51–52
short stay units (SSUs), 292, 480
SI. See severity of illness
sickle cell disease (SCD), 244, 251,
473
adjunctive therapy, 247–248
admission criteria, 246–247
clinical pathway, 246
consults, 246
current management, 245
evidence basis, 462
individualized treatment
regimens, 246
management goals, 245–248
observation protocol, 247
opioids for, 246
pathway metrics, 247
pitfalls in management, 248
in United Kingdom observation
medicine, 422
simethicone, 746
simple observation, 12–15
sinovastatin, 742
Singapore observation medicine
asthma in, 405
challenges, 403
COPD in, 405
origins, 403
protocols, 403–404
role of, 405
staffing in, 403
unique features of, 404–405
789
single positron emission computed tomography (SPECT), 128–130
six sigma, 48
skilled nursing facility (SNF), 767
sleeping pills, 757
smoking
cessation, 747
readmissions and, 81
SNF. See skilled nursing facility
social resources, 58–59
Social Security Act of 1965, 370–371
social workers, 411
Society for Academic Emergency Medicine (SAEM), 23–24
Society of Chest Pain Centers, 25, 32
Society of Hospital Medicine, 5
sodium, 240
sodium polystyrene sulfonate (SPS), 237
soft tissue infections (SSITs), 257
antibiotic therapy, 261
classification system, 259
clinical presentation, 257–258
conditions mimicking, 260
discharge criteria, 260–261
imaging, 258
laboratory evaluation, 258
management, 260
non-suppurative, 257
observation unit, 259–260
patient selection criteria, 258–260
transfer criteria, 260–261
South Africa
emergency center observation wards, 398–399
emergency medicine in, 398
Special Health Care Needs (SHCN), 292
special needs shelter, 343–344
SPECT. See single positron emission computed tomography
spinal cord, 192–193
in pain pathophysiology, 195
spinal headaches, 643, 745
SPS. See sodium polystyrene sulfonate
SSITs. See soft tissue infections
SSUs. See short stay units
St. Thomas’ Hospital, 421
staffing, 38–39.
See also specific staff
acute care, 28
additional personnel, 6–7
administrative, 7
advanced practice providers, 5–6
alternative care facilities, 341
ancillary, 31–32
background, 589
EDOU, 35
objectives, 589
policies, 589
CDU, 58–59
census, 40–41
clinical care pathways, 31–32
cost analysis, 41
evolution of, 24
flexible, 4
midlevel provider, 39
background, 584
coverage, 5–6, 33–34
discussion, 585
objectives, 584
policy, 584
staffing ratios, 39
models, 33–34
nurse staffing ratios, 4–5, 38
patient satisfaction, 5
physicians, 5
ratios, 39
pulling, 41
in Singapore observation medicine, 403
stakeholder analysis
APCs in, 384
business model, 382–384
hospital administrators in, 384
Medicare in, 383–384
nurses in, 384
patients in, 382–384
payers in, 384
physicians in, 384
STEMI, 413–415
ECG for, 101
steroids, 742
Strengths, Weaknesses, Opportunities, Threats (SWOT), 382
Streptococcus pneumoniae, 147
stress cardiovascular magnetic resonance imaging, 130
characteristics, 130
stress echocardiogram, 130
characteristics, 131
stress electrocardiogram, 128
stress myocardial perfusion imaging, 131
stress tests, 38
CTCA, 130
management, 131
nuclear, 128–130
outcome, 131
patient characteristics, 131
pharmacologic, 127–129
preparation for, 131
pretest probability, 127–128
types of, 128–130
in women, 130–131
stroke
anticoagulation for, 185
aspirin for, 184
clopidogrel for, 184
dipyridamole for, 184
following TIA, 181
medical management, 184
observation, 185
ticlopidine for, 184
structural indicators, 53
subarachnoid hemorrhage (SAH), 189
subcutaneous calcitonin, 239
subcutaneous vitamin K, 175
substance abuse, 515–516
substance P, 193
ampicillin with, 735, 755
sulfafethoxazole, 756
order sets, 737
sulfonylureas toxicity admission criteria, 325
contraindications to admission, 325
discharge criteria, 326
management, 326
sumatriptan, 744–745
supervising physician, 35
surgical emphysema, 155
SWOT. See Strengths, Weaknesses, Opportunities, Threats
synaptic transmission, 204–205 syncope
classification of, 122
CT of, 124
definition, 121
differential diagnosis, 121
echocardiography for, 124
electrocardiographic monitoring, 124
electrophysiology of, 124
etiologies, 122
evidence basis, 447–449
exclusion criteria, 123
graded exercise testing, 124
inclusion criteria, 123
management, 123
orthostatic, 122
outcomes, 124
pathophysiology, 122
tilt-table testing, 124
systemic corticosteroids, 140
TACO. See transfusion-associated circulatory overload
Tax Relief and Health Care Act, 374
tazobactam, 756
TCC. See trigeminocervical complex
technetium-99m, 103, 128–130
TEE. See transesophageal echocardiography
telemetry systems, 31, 101
telephone
follow-up phone calls, 82
lines, 39
in observation unit, 39
tension pneumothorax, 155

© in this web service Cambridge University Press
www.cambridge.org
tertiary care hospitals, 62
CMS and, 63
definition, 62–63
finances of, 63
optimal size of, 63
RAC in, 63
referral to, 62
Texas Childrens Hospital, 301–302
ThA. See total hip arthroplasty
thallium-201, 128–130
thiopryline, 140
Third Level appeal, 379
third party payers, 370–371
thrombocytopenia, 169–170, 252
thromboembolism, 116
Thrombolysis in Myocardial Infarction (TIMI), 100, 103
thrombotic thrombocytopenic purpura (TTP), 251–253, 255
TIA. See transient ischemic attack
ticlopidine, 184
tilt-table testing, 124
time, tincture of, 27
time lag, 40
TIMI. See Thrombolysis in Myocardial Infarction
tincture of time, 27
tinzaparin, 743
tip on needle thoracocentesis, 549
TKA. See total knee arthroplasty
tMF Health Quality Institute, 373
toileting, 39
Toradol, 744, 754
order sets, 735
total hip arthroplasty (THA), 78
total knee arthroplasty (TKA), 78
toxicology, 560
acetaminophen
admission criteria, 323–324
contraindications to admission, 323–324
discharge criteria, 324
management, 324
benzodiazepines
admission criteria, 324
contraindications to admission, 324
discharge criteria, 324
management, 324
reversal, 325
bupropion
admission criteria, 325
contraindications for admission, 325
discharge criteria, 325
management, 325
carbon monoxide
admission criteria, 326
contraindications to admission, 326
discharge criteria, 326
management, 326
crotalid envenomation
admission criteria, 328
antivenom, 329
contraindications to admission, 328
management, 328
ED visits from, 323
evidence basis, 455–456, 463
Latrodectus mactans
envenomation
admission criteria, 328
contraindications to admission, 328
management, 327
opioids
admission criteria, 326
contraindications to admission, 327
discharge criteria, 328
management, 327
trimethobenzamide, 757
trimethoprim, 756
troponin, 101
trigeminothalamic tract, 193
tricyclic antidepressants, 196
triazolam, 739
tricyclic antidepressants, 196
trigeminocephalовic complex (TCC), 191
trigeminalthalamic tract, 193
trimethobenzamide, 757
order sets, 738
trimethoprim, 756
order sets, 737
troponin, 101–102
chest pain and, 102
TTE. See transthoracic echocardiography
TTMI. See Thrombolysis in Myocardial Infarction
ttime lag, 40
tip on needle thoracocentesis, 549
TKA. See total knee arthroplasty
total hip arthroplasty (THA), 78
toxicology, 560
acetaminophen
admission criteria, 323–324
contraindications to admission, 323–324
discharge criteria, 324
management, 324
benzodiazepines
admission criteria, 324
contraindications to admission, 324
discharge criteria, 324
management, 324
reversal, 325
bupropion
admission criteria, 325
contraindications for admission, 325
discharge criteria, 325
management, 325
carbon monoxide
admission criteria, 326
contraindications to admission, 326
discharge criteria, 326
management, 326
crotalid envenomation
admission criteria, 328
antivenom, 329
contraindications to admission, 328
management, 328
ED visits from, 323
evidence basis, 455–456, 463
Latrodectus mactans
envenomation
admission criteria, 328
contraindications to admission, 328
management, 327
opioids
admission criteria, 326
contraindications to admission, 327
discharge criteria, 328
management, 327
trimethobenzamide, 757
trimethoprim, 756
troponin, 101
trigeminothalamic tract, 193
tricyclic antidepressants, 196
triazolam, 739
tricyclic antidepressants, 196
trigeminocephalовic complex (TCC), 191
trigeminalthalamic tract, 193
trimethobenzamide, 757
order sets, 738
trimethoprim, 756
order sets, 737
troponin, 101–102
chest pain and, 102
TTE. See transthoracic echocardiography
TTMI. See Thrombolysis in Myocardial Infarction
time lag, 40
tip on needle thoracocentesis, 549
TKA. See total knee arthroplasty
total hip arthroplasty (THA), 78
toxicology, 560
acetaminophen
admission criteria, 323–324
contraindications to admission, 323–324
discharge criteria, 324
management, 324
benzodiazepines
admission criteria, 324
contraindications to admission, 324
discharge criteria, 324
management, 324
reversal, 325
bupropion
admission criteria, 325
contraindications for admission, 325
discharge criteria, 325
management, 325
carbon monoxide
admission criteria, 326
contraindications to admission, 326
discharge criteria, 326
management, 326
crotalid envenomation
admission criteria, 328
antivenom, 329
contraindications to admission, 328
management, 328
ED visits from, 323
evidence basis, 455–456, 463
Latrodectus mactans
envenomation
admission criteria, 328
contraindications to admission, 328
management, 327
opioids
admission criteria, 326
contraindications to admission, 327
discharge criteria, 328
management, 327
trimethobenzamide, 757
trimethoprim, 756
troponin, 101
trigeminothalamic tract, 193
tricyclic antidepressants, 196
triazolam, 739
tricyclic antidepressants, 196
trigeminocephalовic complex (TCC), 191
trigeminalthalamic tract, 193
trimethobenzamide, 757
order sets, 738
trimethoprim, 756
order sets, 737
troponin, 101–102
chest pain and, 102
TTE. See transthoracic echocardiography
TTMI. See Thrombolysis in Myocardial Infarction
time lag, 40
tip on needle thoracocentesis, 549
TKA. See total knee arthroplasty
total hip arthroplasty (THA), 78
toxicology, 560
acetaminophen
admission criteria, 323–324
contraindications to admission, 323–324
discharge criteria, 324
management, 324
benzodiazepines
admission criteria, 324
contraindications to admission, 324
discharge criteria, 324
management, 324
reversal, 325
bupropion
admission criteria, 325
unfractionated heparin (UFH), 169
unit coordinators, 589
United Kingdom observation medicine
EMU in, 421
GDO in, 421–422
history of, 421
outcomes, 422–423
sickle cell disease in, 422
United States age-related observation in, 484
commercially available drugs in, 513
ergiatric patients in, 483–484
health care in, 45
spending, 484
hospital savings in, 479
unstable angina (UA), 101
upper gastrointestinal bleeding (UGIB)
discussion, 267–268
exclusion criteria, 267
outcome, 268–269
patient criteria, 267
risk stratification, 268
UR. See Utilization Review
urban community hospital ED, 60
observation medicine in, 60
successful operation, 60
urinalysis, 275
urinary tract infection (UTI), 280
inclusions, 281
interventions, 281–282
management, 281–282
outcomes, 282
pathophysiology, 280–281
uro lithiasis, 274
UTI. See urinary tract infection
Utilization Committee, 17–18
Utilization Review (UR), 89–90, 360, 367
eyear of, 370
performing, 89
vaginal bleeding, 287
management, 287
outcome, 287–288
patient criteria, 287
valproate, 745
VAP. See ventilator associated pneumonia
vascular imaging, 183
vaso-occlusive crisis (VOC), 244, 245, 244
adjunctive therapy, 247–248
admission criteria, 246–247
clinical pathway, 246
consults, 246–247
individualized treatment regimens, 246
management goals, 245–248
observation protocol, 247
opioids for, 246
pitfalls in management, 248
VATS. See video-assisted thoracoscopic surgery
venous thromboembolism (VTE), 159, 173
diagnosis, 159–160
discussion, 159–160
order set, 702–704
outcome, 163
symptoms, 159
treatment, 159–160
ventilation-perfusion scintigraphy (V/Q scan), 166–167
ventilator associated pneumonia (VAP), 149
ventral posteromedial thalamic nucleus (VPM), 193
vertebrocentral causes, 218–220
clinical protocols, 522–523
differential diagnosis, 215–218
discharge criteria, 522–523
disposition criteria, 522–523
exclusion criteria, 522
inclusion criteria, 522
inpatient admission, 522
observation unit interventions, 522
timeframe, 523
vestibular causes of, 217
Veterans Health Administrations (VHA), 78
video-assisted thoracoscopic surgery (VATS), 155
vital signs, 312
in abdominal pain order set, 602
in AF order sets, 613
vitamin B6, 290
vitamin K antagonists, 615, 703
anticoagulation reversal with, 175
epoxide reductase, 175
intravenous, 175
oral administration, 175
reductase, 175
succinone, 175
vitamin K agonist (VKA), 160, 167–169
vitamin K oxide reductase (VKOR), 174
VKA. See vitamin K agonist
VKOR. See vitamin K oxide reductase
VOC. See vaso-occlusive crisis
V/Q scan. See ventilation-perfusion scintigraphy
VTE. See venous thromboembolism
vWD. See von Willebrand disease
vWF. See von Willebrand factor
VPM. See ventral posteromedial thalamic nucleus
V/Q scan. See ventilation-perfusion scintigraphy
VTE. See venous thromboembolism
vWD. See von Willebrand disease
VWF. See von Willebrand factor
waiting rooms, 43
warfarin therapy, 116, 160, 252, 742–743
commercially distributed, 173–174
dose, 174
FFP and, 252
history of, 173
onset of, 174
pharmacology, 173–174
reversal, 252
WBC. See white blood cell count
WellPoint, 370–371
Wells rule, 165–166
Western Cape Package of Care, 400
white blood cell count (WBC), 258, 275
women, stress tests in, 130–131
Y-model, 393–394
quality and cost focus of, 393
zig-zag model of care, 394
zolpidem, 739
Zone Program Integrity Contractors, 22
ZPIC. See Zone Program Integrity Contractors